CJC-1295

CJC-1295 – GHRH analogue for growth hormone research

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue modified to increase the half-life of the molecule in a research setting. The peptide consists of 30 amino acids and is one of the most frequently used tools in research on the somatotropic axis. Its ability to stimulate the GHRH-R receptor has been demonstrated in animal models. Substance intended for research use only (Research Use Only). Browse CJC-1295 variants from One Peptides or read on to learn more about this peptide.

What is CJC-1295?

CJC-1295 is a synthetic peptide of 30 amino acids, developed as a modified analogue of human GHRH (Growth Hormone Releasing Hormone, amino acids 1–29). Modifications to the molecular structure, including amino acid substitutions at positions 2, 8, 15 and 27, were intended to increase resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), the enzyme responsible for the rapid degradation of native GHRH in plasma.

The history of CJC-1295 dates back to research conducted in the early 2000s by ConjuChem (hence the acronym CJC). This peptide was created as a tool to study the mechanisms of regulation of the somatotropic axis – the system responsible for the production and secretion of growth hormone (GH) from the anterior pituitary gland.

The mechanism of action of CJC-1295 is to bind to the GHRH-R receptor on the surface of pituitary somatotropes, which in animal models leads to stimulation of GH secretion in a pulsatile manner – similar to the physiological secretion pattern. A secondary increase in IGF-1 (insulin-like growth factor 1) levels was also observed in in vivo studies in animal models.

CJC-1295 is not a drug, dietary supplement or medicinal product. It is a substance intended only for laboratory tests.

CJC-1295 variants available

The product is supplied with a Certificate of Analysis (CoA) including HPLC and MS results. Full physicochemical data available on the product page.

Which CJC-1295 variant should I choose?

CJC-1295 (without DAC) is available from One Peptides in the form of a lyophilized product containing 5 mg of substance per vial. This amount allows for both pilot experiments on cell cultures and extensive research series on animal models. The content of 5 mg provides enough material to prepare working solutions of various concentrations, adapted to the specificity of the experimental protocol.

When choosing between CJC-1295 and the version with DAC, consider the research goal – CJC-1295 without DAC generates pulsatile stimulation of the GHRH-R receptor, similar to the physiological pattern of GH secretion, which makes it a suitable tool for research on acute stimulation of the somatotropic axis.

Once reconstituted, the CJC-1295 solution should be stored at 2-8 degrees Celsius and used within a few days. Store the lyophilisate in its original packaging at a temperature below -20 degrees Celsius.

How is CJC-1295 different from similar peptides?

CJC-1295 vs CJC-1295 DAC

CJC-1295 DAC (Drug Affinity Complex) is a version of the CJC-1295 peptide conjugated to a DAC molecule, a drug affinity complex that binds to albumin in the blood. This modification significantly increases the plasma half-life of the peptide from minutes (native CJC-1295) to several days in animal models. CJC-1295 without DAC generates shorter, more physiological pulses of GH stimulation, while the DAC version maintains elevated GH levels for a longer time. The choice between variants depends on the designed research protocol. See category: CJC DAC

CJC-1295 vs GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a hexapeptide that acts through the ghrelin receptor (GHS-R1a) – a completely different pathway than the GHRH-R receptor that CJC-1295 acts on. In animal models, a synergistic effect was observed when both peptides were used in parallel – stimulation of two independent pathways led to an enhanced somatotropic response. CJC-1295 and GHRP-6 are therefore not competitive, but complementary research tools. See category: GHRP-6

FAQ – Frequently asked questions

1. What is CJC-1295?
CJC-1295 is a synthetic analogue of GHRH (growth hormone releasing hormone), consisting of 30 amino acids. Developed by ConjuChem as a research tool for the analysis of the somatotropic axis. It is available as a lyophilized product for research use only.

2. What is the difference between CJC-1295 and CJC-1295 DAC?
CJC-1295 without DAC is a pure peptide with a short half-life that generates pulsatile stimulation of the GHRH-R receptor. The DAC (Drug Affinity Complex) version is conjugated to an albumin-binding molecule, which extends the duration of action from minutes to days in animal models.

3. Is CJC-1295 a drug or dietary supplement?
NO. CJC-1295 offered at One Peptides is a substance intended exclusively for scientific research (Research Use Only). It is not a medicinal product, drug or dietary supplement.

4. How should CJC-1295 be stored?
Store the lyophilisate at a temperature below -20 degrees Celsius. After reconstitution, the solution should be stored at 2-8 degrees Celsius and used within a short period of time or divided into aliquots and frozen.

5. What signaling pathways does CJC-1295 engage?
CJC-1295 binds to the GHRH-R receptor on pituitary somatotropes, activating the cAMP/PKA pathway, which in animal models leads to stimulation of the secretion of growth hormone (GH) and, secondarily, insulin-like growth factor (IGF-1).

Quality and standards at One Peptides

All peptides in the One Peptides catalogue, including CJC-1295, are subject to rigorous quality control. Each batch is analyzed by HPLC (High-Performance Liquid Chromatography) to confirm purity and mass spectrometry (MS) to verify molecular identity. Each product is accompanied by a Certificate of Analysis (CoA) and a Safety Data Sheet (SDS). This translates into the repeatability and reliability of research results.